Cargando…

Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway

Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients. Abrocitinib, a Janus kinase1 (JAK1) selective inhibitor approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tuo, Li, Lei, Peng, Ruilong, Hao, Hongying, Zhang, Hejun, Gao, Yalong, Wang, Cong, Li, Fanjian, Liu, Xilei, Chen, Fanglian, Zhang, Shu, Zhang, Jianning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688110/
https://www.ncbi.nlm.nih.gov/pubmed/36429017
http://dx.doi.org/10.3390/cells11223588
_version_ 1784836184081432576
author Li, Tuo
Li, Lei
Peng, Ruilong
Hao, Hongying
Zhang, Hejun
Gao, Yalong
Wang, Cong
Li, Fanjian
Liu, Xilei
Chen, Fanglian
Zhang, Shu
Zhang, Jianning
author_facet Li, Tuo
Li, Lei
Peng, Ruilong
Hao, Hongying
Zhang, Hejun
Gao, Yalong
Wang, Cong
Li, Fanjian
Liu, Xilei
Chen, Fanglian
Zhang, Shu
Zhang, Jianning
author_sort Li, Tuo
collection PubMed
description Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients. Abrocitinib, a Janus kinase1 (JAK1) selective inhibitor approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA), possesses a novel anti-inflammatory effect. In this study, we investigated whether abrocitinib could ameliorate neuroinflammation and exert a neuroprotective effect in traumatic brain injury (TBI) models. Methods: First, next-generation sequencing (NGS) was used to select genes closely related to neuroinflammation after TBI. Then, magnetic resonance imaging (MRI) was used to dynamically observe the changes in traumatic focus on the 1st, 3rd, and 7th days after the induction of fluid percussion injury (FPI). Moreover, abrocitinib’s effects on neurobehaviors were evaluated. A routine peripheral blood test was carried out and Evans blue dye extravasation, cerebral cortical blood flow, the levels of inflammatory cytokines, and changes in the numbers of inflammatory cells were evaluated to investigate the function of abrocitinib on the 1st day post-injury. Furthermore, the JAK1/signal transducer and activator of transcription1 (STAT1)/nuclear factor kappa (NF-κB) pathway was assessed. Results: In vivo, abrocitinib treatment was found to shrink the trauma lesions. Compared to the TBI group, the abrocitinib treatment group showed better neurological function, less blood-brain barrier (BBB) leakage, improved intracranial blood flow, relieved inflammatory cell infiltration, and reduced levels of inflammatory cytokines. In vitro, abrocitinib treatment was shown to reduce the pro-inflammatory M1 microglia phenotype and shift microglial polarization toward the anti-inflammatory M2 phenotype. The WB and IHC results showed that abrocitinib played a neuroprotective role by restraining JAK1/STAT1/NF-κB levels after TBI. Conclusions: Collectively, abrocitinib treatment after TBI is accompanied by improvements in neurological function consistent with radiological, histopathological, and biochemical changes. Therefore, abrocitinib can indeed reduce excessive neuroinflammation by restraining the JAK1/STAT1/NF-κB pathway.
format Online
Article
Text
id pubmed-9688110
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96881102022-11-25 Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway Li, Tuo Li, Lei Peng, Ruilong Hao, Hongying Zhang, Hejun Gao, Yalong Wang, Cong Li, Fanjian Liu, Xilei Chen, Fanglian Zhang, Shu Zhang, Jianning Cells Article Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients. Abrocitinib, a Janus kinase1 (JAK1) selective inhibitor approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA), possesses a novel anti-inflammatory effect. In this study, we investigated whether abrocitinib could ameliorate neuroinflammation and exert a neuroprotective effect in traumatic brain injury (TBI) models. Methods: First, next-generation sequencing (NGS) was used to select genes closely related to neuroinflammation after TBI. Then, magnetic resonance imaging (MRI) was used to dynamically observe the changes in traumatic focus on the 1st, 3rd, and 7th days after the induction of fluid percussion injury (FPI). Moreover, abrocitinib’s effects on neurobehaviors were evaluated. A routine peripheral blood test was carried out and Evans blue dye extravasation, cerebral cortical blood flow, the levels of inflammatory cytokines, and changes in the numbers of inflammatory cells were evaluated to investigate the function of abrocitinib on the 1st day post-injury. Furthermore, the JAK1/signal transducer and activator of transcription1 (STAT1)/nuclear factor kappa (NF-κB) pathway was assessed. Results: In vivo, abrocitinib treatment was found to shrink the trauma lesions. Compared to the TBI group, the abrocitinib treatment group showed better neurological function, less blood-brain barrier (BBB) leakage, improved intracranial blood flow, relieved inflammatory cell infiltration, and reduced levels of inflammatory cytokines. In vitro, abrocitinib treatment was shown to reduce the pro-inflammatory M1 microglia phenotype and shift microglial polarization toward the anti-inflammatory M2 phenotype. The WB and IHC results showed that abrocitinib played a neuroprotective role by restraining JAK1/STAT1/NF-κB levels after TBI. Conclusions: Collectively, abrocitinib treatment after TBI is accompanied by improvements in neurological function consistent with radiological, histopathological, and biochemical changes. Therefore, abrocitinib can indeed reduce excessive neuroinflammation by restraining the JAK1/STAT1/NF-κB pathway. MDPI 2022-11-13 /pmc/articles/PMC9688110/ /pubmed/36429017 http://dx.doi.org/10.3390/cells11223588 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Tuo
Li, Lei
Peng, Ruilong
Hao, Hongying
Zhang, Hejun
Gao, Yalong
Wang, Cong
Li, Fanjian
Liu, Xilei
Chen, Fanglian
Zhang, Shu
Zhang, Jianning
Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title_full Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title_fullStr Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title_full_unstemmed Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title_short Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway
title_sort abrocitinib attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting the jak1/stat1/nf-κb pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688110/
https://www.ncbi.nlm.nih.gov/pubmed/36429017
http://dx.doi.org/10.3390/cells11223588
work_keys_str_mv AT lituo abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT lilei abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT pengruilong abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT haohongying abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT zhanghejun abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT gaoyalong abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT wangcong abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT lifanjian abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT liuxilei abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT chenfanglian abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT zhangshu abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway
AT zhangjianning abrocitinibattenuatesmicrogliamediatedneuroinflammationaftertraumaticbraininjuryviainhibitingthejak1stat1nfkbpathway